Seminar on nasopharyngeal cancer

Seminar on nasopharyngeal cancer

12 November 2015
Nasopharyngeal cancer is a rare disease in Europe, with an annual incidence of less than 1 out of 100,000 citizens. This disease has a high chemo- and radiosensitivity, allowing 5-year survival rates of 80-90% for early stages (I-II) and 60-70% for advanced stages (III-IV). The treatment of NPC has issued numerous challenges in the last decade:
  • The possibility of reducing the toxicity of radiation treatment with the use of intensity-modu- lated techniques
  • An increase in the use of chemotherapy with a radiosensitizing function and to reduce the risk of distant metastases
  • Thefeasibilityofnewdirectimmunetherapiestakingadvantageofthelinkofthetumorwith EBV
  • The treatment of locoregional recurrence to maximize response and survival
  • Supportive care to reduce the toxicity induced by the cancer treatments
  • The best multidisciplinary management of the disease
For these reasons, this seminar on nasopharyngeal cancer will allow the various specialists involved to be up-to-date, as well as presenting the most recent therapeutic developments. Download NPC seminar program